Therapy

HSS Receives Betty J. Cleckley Minority Issues Research Award from American Public Health Association

Monday, October 25, 2021 - 11:00pm

NEW YORK, Oct. 25, 2021 /PRNewswire/ --The Department of Community Education & Outreach at Hospital for Special Surgery (HSS) has received the Betty J. Cleckley Minority Issues Research Award at the American Public Health Association (APHA) annual meeting.

Key Points: 
  • NEW YORK, Oct. 25, 2021 /PRNewswire/ --The Department of Community Education & Outreach at Hospital for Special Surgery (HSS) has received the Betty J. Cleckley Minority Issues Research Award at the American Public Health Association (APHA) annual meeting.
  • The award recognizes individuals in aging and public health research who have made a significant impact on the lives of older people who are members of minority groups, according to the APHA.
  • The organization notes that minimizing health disparities and improving access to health and long-term care services are important issues for minority populations in the United States.
  • HSS is the award recipient for its manuscript titled, "Utilizing Alternative Strategies to Keep Underserved and Vulnerable Communities Socially Connected."

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monday, October 25, 2021 - 9:45pm

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.

Key Points: 
  • NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 44,000 shares of common stock to Mary Grendell, Protaras new General Counsel.
  • The Compensation Committee of Protaras Board of Directors approved the awards as an inducement material to Ms. Grendells employment in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
  • For more information, visit www.protaratx.com

89bio to Present New Sub-Analysis from Phase 1b/2a NASH Study of BIO89-100 at AASLD’s The Liver Meeting 2021

Monday, October 25, 2021 - 9:05pm

The presentations will also be available on the 89bio website after the meeting.

Key Points: 
  • The presentations will also be available on the 89bio website after the meeting.
  • FGF21 is an endogenous hormone that modulates important drivers of NASH including glycemic control, steatosis, inflammation and fibrosis.
  • 89bio has advanced BIO89-100 into the Phase 2b ENLIVEN trial in NASH, which is now ongoing.
  • 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

Monday, October 25, 2021 - 9:05pm

The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .

Key Points: 
  • The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm .
  • Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases.
  • The company is led by a management team experienced in the development and commercialization of rare disease therapeutics.
  • For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .

OPY Acquisition Corp. I Announces Launch of $100 Million Initial Public Offering

Monday, October 25, 2021 - 9:01pm

Each whole warrant will entitle the holder thereof to purchase one share of Class A common stock at $11.50 per share.

Key Points: 
  • Each whole warrant will entitle the holder thereof to purchase one share of Class A common stock at $11.50 per share.
  • Oppenheimer & Co. Inc. and Lake Street Capital Markets are acting as joint book-running managers for the offering.
  • This press release contains statements that constitute forward-looking statements, including with respect to the Companys initial public offering (IPO) and search for an initial business combination.
  • Forward-looking statements are subject to numerous conditions, many of which are beyond the control of OPY Acquisition Corp.

Lantern Pharma to Host Third Quarter 2021 Operating & Financial Results Conference Call on Monday, November 1, 2021 at 4:30 p.m. ET

Monday, October 25, 2021 - 9:57pm

DALLAS, Oct. 25, 2021 /PRNewswire/ --Lantern Pharma(NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.")

Key Points: 
  • DALLAS, Oct. 25, 2021 /PRNewswire/ --Lantern Pharma(NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.")
  • Management intends to discuss the financial and operating results for the third quarter ended September 30, 2021 and provide guidance on upcoming milestones.
  • The call will be led by Panna Sharma, President and Chief Executive Officer of Lantern Pharma.
  • Lantern is currently developing four drug candidates and an ADC program across eight disclosed tumor targets, including two phase 2 programs.

Statement from Akebia Therapeutics Regarding Litigation Against Centers for Medicare & Medicaid Services and the U.S. Department of Health and Human Services

Monday, October 25, 2021 - 9:39pm

We also asked the federal district courttoissue an injunction to immediately restorecoverageforAuryxiawhen used forIDA while the lawsuit was pending.

Key Points: 
  • We also asked the federal district courttoissue an injunction to immediately restorecoverageforAuryxiawhen used forIDA while the lawsuit was pending.
  • Unfortunately, thefederal district courtdeniedour motionforapreliminaryinjunctionand the U.S. Court of Appeals for the First Circuit affirmed the district court's decision.
  • All eligible patients deserve access to, and Medicare coverage for, critical, innovative therapies such as Auryxia for chronic kidney disease.
  • However, an overdose of iron in pregnant women may carry a risk for spontaneous abortion, gestational diabetes and fetal malformation.

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Monday, October 25, 2021 - 9:01pm

The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $172.5 million.

Key Points: 
  • The gross proceeds to Crinetics from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $172.5 million.
  • SVB Leerink, Evercore ISI and Cantor acted as joint bookrunning managers for the offering.
  • H.C. Wainwright & Co. acted as lead manager and JonesTrading acted as co-manager for the offering.
  • Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment ofcarcinoid syndromeassociated with neuroendocrine tumors.

Palleon to Present Preclinical Data on Lead Immuno-Oncology Program, E-602, at SITC Annual Meeting

Monday, October 25, 2021 - 9:00pm

Palleon Pharmaceuticals , a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the companys lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.

Key Points: 
  • Palleon Pharmaceuticals , a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced it will present new preclinical data on the companys lead immuno-oncology program, E-602, at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C., from November 10-14, 2021.
  • Palleons poster highlights recent preclinical data from in vitro and in vivo studies of the companys most advanced therapeutic candidate, E-602 (formerly known as Bi-Sialidase).
  • E-602 is part of the companys novel cancer immunotherapy platform, EAGLE (Enzyme-Antibody Glycan-Ligand Editing), which utilizes engineered human sialidase to degrade immunosuppressive sialoglycans.
  • These data will inform our upcoming Phase 1 clinical trial of E-602, as well as our growing pipeline of EAGLE therapeutic candidates in oncology.

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

Monday, October 25, 2021 - 9:00pm

Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.

Key Points: 
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).
  • In addition, please connect with us on Twitter and LinkedIn .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20211025005719/en/